Jefferies initiates Arrowhead Research at Buy on RNAi platform potential

|About: Arrowhead Pharmaceuticals (ARWR)|By:, SA News Editor

Recent private offering placement agent Jefferies initiates coverage on Arrowhead Research (ARWR +4.3%) with a Buy and PT of $15.

Analyst Thomas Wei believes Arrowhead's differentiated RNAi platform is its "key value driver." And, as ARC-520 for hepatitis B progresses, "it should provide confidence around safety and mechanistic validation for the technology, even if HBV cures are not achieved. We expect expansion into liver targeted orphan diseases should create significant value."